866-997-4948(US-Canada Toll Free)

Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors - Pipeline Insights, 2016

Published By :

DelveInsight

Published Date : Jul 2016

Category :

Oncology

No. of Pages : 102 Pages

DelveInsights, Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors-Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
The new report, provides a Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors Landscape across the globe
The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
Coverage of the Bromodomain and Extra-terminal Domain Protein (BET) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for BET Inhibitors and also provide company profiling
Pipeline products coverage based on various stages of development from NDA filings to discovery.
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Table of Contents
Overview
Epidemiology
Market Scenario
Pipeline Therapeutics
An Overview of Pipeline Products for BET Inhibitors
Therapeutics under Development by Companies
Late Stage Products (Filed and Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Product Description
Product Development Activities
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Discontinued Products
Dormant Products
Companies involved in Therapeutics Development
Appendix
Methodology
Consulting Services
Disclaimer
Report Purchase Options
About DelveInsight
Contact Us

List of Tables

Table 1: Number of Products Under Development, 2016
Table 2: Number of Products under Development by Companies, 2016
Table 3: Last Stage Products (Phase III and Filed), 2016
Table 4: Mid Stage Products (Phase II), 2016
Table 5: Early Stage Products (Phase I and IND), 2016
Table 6: Phase 0 stage Products , 2016
Table 7: Discovery and Pre-clinical Stage Products , 2016
Table 8: Assessment by Monotherapy Products,2016
Table 9: Assessment by Route Of Administration, 2016
Table 10: Assessment by Stage and Route Of Administration, 2016
Table 11: Assessment by Molecule Type, 2016
Table 12: Assessment by Stage and Molecule Type, 2016
Table 13: Discontinued Products, 2016
Table 14: Dormant Products, 2016
Table 15: Companies Involved in Therapeutic Development, 2016

List of Figures

Figure 1: Number of Products under Development for BET Inhibitors ,2016
Figure 2: Late Stage Products (Filed and Phase III),2016
Figure 3: Mid Stage Products (Phase II),2016
Figure 4: Early Stage Products (Phase I and IND),2016
Figure 5: Discovery and Pre-clinical Stage Products, 2016
Figure 6: Assessment by Monotherapy Products, 2016
Figure 7: Assessment by Combination Products, 2016
Figure 8: Assessment by Route of Administration, 2016
Figure 9: Assessment by Stage and Route of Administration, 2016
Figure 10: Assessment by Molecule Type, 2016
Figure 11: Assessment by Stage and Molecule Type, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *